Critical Injury (Trauma) in Children
Conditions
Keywords
pediatric, trauma, critical, GM-CSF, immune
Brief summary
The GIFT study is a prospective, multi-center, interventional trial using the drug GM-CSF for the reversal of innate immune suppression in critically injured children. The study will be conducted in two phases, a dose-finding phase then an efficacy phase. The dose-finding phase is the current active phase of the study. The central hypothesis of the study is that immunomodulation with GM-CSF will result in reduction in the risk of nosocomial infection after critical injury in high-risk children through safe, rapid, and sustained improvement in innate immune function.
Detailed description
The current phase of the study is an open-label dose-finding phase in which critically injured children undergo prospective, serial immune function testing in the first few days after injury. If a subject's immune function (as measured by whole blood ex vivo LPS-induced TNF-alpha production capacity) is below a critical threshold, the subject will receive GM-CSF at a dose of 30, 62, or 125 mcg/m2 per day for three days. Enrollment is stratified by pubertal status (Tanner 1 or Tanner \> 1) and by presence or absence of severe traumatic brain injury (TBI). Dose-finding is being conducted independently in each of these strata. The outcome variable for the dose-finding phase of the GIFT study is restoration of TNF-alpha production capacity and monocyte HLA-DR expression by the end of treatment, persisting to post-trauma day 7. A subsequent randomized, placebo-controlled trial with nosocomial infection as the primary outcome variable is planned once dose-finding is complete. This study is being conducted by the NICHD's Collaborative Pediatric Critical Care Research Network (CPCCRN) with Nationwide Children's Hospital as the primary site. The study design information currently displayed on this site refers to the dose-finding phase of the project.
Interventions
DRUGGM-CSF
GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
Sponsors
National Institute of General Medical Sciences (NIGMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Mark Hall
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Admission to the PICU at a GIFT study site with a primary diagnosis of blunt or penetrating trauma that occurred within the last 72 hours. * Age 1 - 17 years * Provisional Injury Severity Score (ISS) \> 10 * Presence of an endotracheal tube at the time of enrollment
Exclusion criteria
* DNR status or care team/family is considering plans for withdrawal of life-sustaining therapies. * Strong suspicion of injuries related to child abuse, in the opinion of the treating physician * Persistence (after treatment) of any of the following in the PICU before enrollment: Fixed, dilated pupils; Glasgow Coma Scale score of 3 (in the absence of neuromuscular blocking drugs); or presence of a new, severe neurologic injury at the time of enrollment which, in the opinion of the treating physician, is highly likely to lead to a diagnosis of brain death * Cardiopulmonary arrest requiring CPR documented by EMS or hospital personnel prior to subject identification * Burn injury of any kind (scald, fire, chemical) * Patients receiving acute or chronic immunosuppressive therapy (e.g., systemic corticosteroids, calcineurin inhibitors, mycophenolate, azathioprine) at the time of injury * Patients with severe leukopenia (white blood cell count \< 1000 cells/mm3) at the time of injury as the result of myeloablative chemotherapy or radiation * Pregnancy * Autoimmune thrombocytopenia, myelodysplastic syndromes with \> 20% marrow blast cells, or known allergy/hypersensitivity to GM-CSF * Previously enrolled in the GIFT study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immune function | 7-days post-trauma | To identify the lowest immunostimulatory yet tolerable dose of GM-CSF that produces lasting improvement in innate immune function in treated children. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nosocomial infection | 28-days post-trauma | The development of hospital-acquired infection through post-trauma day 28 |
Countries
United States
Outcome results
None listed